FLOW

Semaglutide and Kidney Outcomes in Type 2 Diabetes with Chronic Kidney Disease

Patient / Population Intervention / Exposition Vergleich Endpunkt

In 3,533 patients with type 2 diabetes and CKD, semaglutide reduced the composite of kidney failure, ≥50% eGFR decline or renal/CV death compared with placebo.

3.533

Design

Double-blind RCT, stopped early

Endpunkt

Kidney failure, ≥50% eGFR decline, or renal or CV death

Relevanz

ErgebnisHR 0.76 (95% CI 0.66–0.88; p=0.0003); all-cause mortality HR 0.80.

Perkovic V, et al. N Engl J Med. 2024;391(2):109-121. 10.1056/NEJMoa2403347

Diskussion & Kritik

First GLP-1-agonist trial with a dedicated renal hard endpoint; the benefit was numerically attenuated in the ~16% on background SGLT2 inhibitors.